Hypertension continuum of care: Blood pressure screening, diagnosis, treatment, and control in a population-based cohort in Haiti.
Haiti
cardiovascular disease
continuum of care
hypertension
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
30
10
2021
received:
03
09
2021
accepted:
09
11
2021
pubmed:
25
2
2022
medline:
8
4
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is the number one cause of death in low-income countries including Haiti, with hypertension (HTN) being the leading risk factor. This study aims to identify gaps in the HTN continuum of screening, diagnosis, treatment, and blood pressure (BP) control. Sociodemographic and clinical data were collected from a population-based sample of adults ≥18 years in Port-au-Prince (PAP) from March 2019 to April 2021. HTN was defined as systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or use of antihypertensive medication. Screening was defined as ever having had a BP measurement; diagnosis as previously being informed of a HTN diagnosis; treatment as having taken antihypertensives in the past 2 weeks; and controlled as taking antihypertensives and having BP < 140/90 mmHg. Factors associated with attaining each step in the continuum were assessed using Poisson multivariable regressions. Among 2737 participants, 810 (29% age-standardized) had HTN, of whom 97% had been screened, 72% diagnosed, 45% treated, and 13% controlled. There were no significant differences across age groups or sex. Obesity (BMI ≥ 30) was a significant factor associated with receiving treatment compared to normal weight (BMI < 25), with a prevalence ratio (PR) of 1.5 (95% CI 1.1-2.0). Having secondary or higher education was associated with higher likelihood of controlled BP (PR 1.9 [95% CI 1.1-3.3]). In this urban Haitian population, the greatest gaps in HTN care are treatment and control. Targeted interventions are needed to improve these steps, including broader access to affordable treatment, timely distribution of medications, and patient adherence to HTN medication.
Identifiants
pubmed: 35199944
doi: 10.1111/jch.14399
pmc: PMC8925011
doi:
Substances chimiques
Antihypertensive Agents
0
Banques de données
ClinicalTrials.gov
['NCT03892265']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
246-254Subventions
Organisme : FIC NIH HHS
ID : D43 TW011972
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL143788
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069421
Pays : United States
Organisme : Resolve to Save Lives
Informations de copyright
© 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Références
Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
J Hypertens. 2019 Apr;37(4):685-695
pubmed: 30817448
BMJ Glob Health. 2017 Aug 16;2(3):e000348
pubmed: 29082013
PLoS One. 2014 Jan 15;9(1):e84238
pubmed: 24454721
J Clin Hypertens (Greenwich). 2022 Mar;24(3):246-254
pubmed: 35199944
BMC Fam Pract. 2012 Mar 26;13:24
pubmed: 22448772
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
Lancet. 2009 Jan 17;373(9659):240-9
pubmed: 19042012
Lancet Glob Health. 2021 Jul;9(7):e967-e976
pubmed: 34143995
Lancet. 2012 Aug 11;380(9841):611-9
pubmed: 22883510
J Hypertens. 2019 Sep;37(9):1813-1821
pubmed: 30964825
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Hypertension. 2019 May;73(5):e35-e66
pubmed: 30827125
BMJ Open. 2020 Sep 9;10(9):e038520
pubmed: 32907906
BMC Public Health. 2020 Nov 1;20(1):1633
pubmed: 33131500
Elife. 2021 Mar 09;10:
pubmed: 33685583
Bull World Health Organ. 2017 Mar 01;95(3):182-190
pubmed: 28250531
Rev Saude Publica. 2008 Dec;42(6):992-8
pubmed: 19009156
N Engl J Med. 2019 Oct 3;381(14):1392
pubmed: 31577888
Front Public Health. 2017 Jan 10;4:296
pubmed: 28119910
J Gen Intern Med. 2005 Mar;20(3):219-25
pubmed: 15836524
J Glob Health. 2021 Apr 17;11:04020
pubmed: 33884191
Hypertension. 2005 Aug;46(2):280-6
pubmed: 15983235
PLoS One. 2020 Jan 15;15(1):e0226286
pubmed: 31940366
BMC Public Health. 2020 Nov 13;20(1):1706
pubmed: 33187491
Circulation. 2018 Oct 23;138(17):e426-e483
pubmed: 30354655
Lancet Public Health. 2017 Sep;2(9):e411-e419
pubmed: 29253412
Front Public Health. 2021 Jan 15;8:600157
pubmed: 33520917
J Clin Nurs. 2018 Jul;27(13-14):2536-2545
pubmed: 29493835
BMC Public Health. 2020 Jun 3;20(1):835
pubmed: 32493255
Hypertension. 2010 Nov;56(5):780-800
pubmed: 20921433
PLoS Med. 2020 Nov 10;17(11):e1003268
pubmed: 33170842
Glob Heart. 2020 Feb 06;15(1):7
pubmed: 32489780
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Cardiol Clin. 2017 Feb;35(1):99-115
pubmed: 27886793
Int J Hypertens. 2020 May 31;2020:8082341
pubmed: 32550019
Lancet. 2019 Aug 24;394(10199):613-615
pubmed: 31327567
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
J Am Board Fam Med. 2008 Jul-Aug;21(4):300-8
pubmed: 18612056
J Am Heart Assoc. 2017 Feb 3;6(2):
pubmed: 28159816
N Engl J Med. 2008 Dec 4;359(23):2417-28
pubmed: 19052124
J Clin Hypertens (Greenwich). 2018 Oct;20(10):1485-1492
pubmed: 30259642